Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 10/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.41 |
| ▸ | SPR | P35270 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20294344 | 0.87 | PDCD1 (0.43) | HTR2CPDCD1CD274SPRRAB9A | |
| SCHEMBL30145307 | 0.87 | PDCD1 (0.43) | HTR2CPDCD1CD274SPRRAB9A | |
| SCHEMBL30145292 | 0.85 | HTR2C (0.41) | HTR2CPDCD1CD274SPR | |
| SCHEMBL20293398 | 0.85 | HTR2C (0.41) | HTR2CPDCD1CD274SPR | |
| SCHEMBL20294409 | 0.82 | PDCD1 (0.51) | HTR2CPDCD1CD274RAB9ANPC1 | |
| SCHEMBL20294060 | 0.81 | PDCD1 (0.49) | HTR2CPDCD1CD274 | |
| SCHEMBL18711325 | 0.79 | GRM5 (0.57) | HTR2CPDCD1CD274SPRRAB9A | |
| SCHEMBL30740239 | 0.78 | GRAMD1A (0.47) | PDCD1CD274SPRRAB9ANPC1 | |
| SCHEMBL19549674 | 0.78 | GRAMD1A (0.47) | PDCD1CD274SPRRAB9ANPC1 | |
| SCHEMBL20294458 | 0.76 | PDCD1 (0.43) | PDCD1CD274RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | INCYTE CORP (US) | 2025-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325660-A1 | IMMUNOMODULATOR COMPOUNDS AND METHODS OF USE | CD274, PDCD1LG2, PDCD1 | HTR2C 2665/4885PDCD1 3/4885CD274 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.